Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs

Kyle LaHucik / endpoints - In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis. The California biopharma could pay out another $1.85 billion down the road ...

AI Summary: Gilead Sciences struck a multibillion-dollar acquisition to add Tubulis and bolster its oncology pipeline, buying into antibody-drug conjugate technology. The deal signals Gilead’s strategic pivot to expand beyond infectious disease into cancer therapeutics, accelerating access to novel modalities and reshaping competitive dynamics in biopharma.

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #oncology #healthcarefinance
Healthcare RSSPharmaceuticals RSSBiotech RSSMergers and Acquisitions RSSCorporate Takeover RSSDrug Development RSSOncology RSSHealthcare Finance RSS

4 ADCs That Rewrote Breast Cancer Treatment History

2 months / oncodaily

Federico Monaca: The Challange is No Longer only ADCs Activity, but also Their Position

2 months / oncodaily

Two New Takes on Making a Type of Targeted Cancer Therapy Even Better

2 months / medcitynews / Frank Vinluan

Yao Zhu: Honored to Host Paolo Tarantino for a Comprehensive Overview of ADC Sequencing

2 months / oncodaily

Oncology Biotech Updates This Week: Gilead’s $5B ADC Acquisition, Tarlatamab’s China Approval, and Why Biology Remains Biotech’s True Bottleneck

2 months / oncodaily

Raffaele Colombo: AMG 133 Discovery Optimization and Development in Preclinical Study

2 months / oncodaily

The Throne Has Changed Hands: T-DXd Displaces T-DM1 in Post-Neoadjuvant HER2+ Breast Cancer

2 months / oncodaily

Gilead Seizes Next-Generation ADC Powerhouse Tubulis in Landmark $5 Billion Oncology Acquisition

3 months / oncodaily

Gilead takes another big swing at expanding beyond HIV

3 months / endpoints / Lei Lei Wu

Gilead’s Pipeline Strategy Takes Shape With $3B Acquisition of Cancer Biotech Tubulis

3 months / medcitynews / Frank Vinluan

Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs

3 months / endpoints / Kyle LaHucik

Best, worst states for children’s healthcare

3 months / beckershospitalreview / Mariah Taylor

Back to Top / Thu, April 9, 2026, 11:22 pm / permalink 21985 / 12 stories in 3 months /




Related Stories

Eli Lilly acquires CrossBridge Bio in oncology deal up to $300M / 2 months

Novartis pays $2B for Synnovation’s next‑gen PI3Kα inhibitor / 3 months

Merck to acquire Terns Therapeutics for $6.7B / 3 months

Novartis buys Myricx Bio to bolster ADC ambitions / 7 hrs

Biogen announces $5.6B acquisition of Apellis Pharma / 3 months

Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 3 months

Servier to acquire Day One Biopharma for $2.5B / 4 months

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Olfaction, Pharmaceuticals, Medicare Advantage (not listed), Diagnostics and look for the RSS link.




↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.